Dr. LaQuisa HIll, MD
Claim this profileBaylor College of Medicine
Studies Acute Lymphoblastic Leukemia
Studies Acute Myelogenous Leukemia
5 reported clinical trials
7 drugs studied
Affiliated Hospitals
Clinical Trials LaQuisa HIll, MD is currently running
MB-105
for T-cell Lymphoma
This is a single arm, two-stage, Phase 2, open-label, multicenter study of MB-105 in patients with CD5 Positive (CD5+) Relapsed / Refractory T-cell Lymphoma (r/r TCL). This study will apply a Simon two-stage optimal design.
Recruiting1 award Phase 26 criteria
CAR T-Cell Therapy
for Blood Cancer
Patients eligible for this study have a type of blood cancer called T-cell leukemia or lymphoma (lymph gland cancer). The body has different ways of fighting infection and disease. This study combines two different ways of fighting disease with antibodies and T cells. Antibodies are types of proteins that protect the body from bacterial and other diseases. T cells, or T lymphocytes, are special infection-fighting blood cells that can kill other cells including tumor cells. Both antibodies and T cells have been used to treat cancer; they have shown promise, but have not been strong enough to cure most patients. T cells can kill tumor cells but there normally are not enough of them to kill all the tumor cells. Some researchers have taken T cells from a person's blood, grown more of them in the laboratory and then given them back to the person. The antibody used in this study is called anti-CD7. This antibody sticks to T-cell leukemia or lymphoma cells because of a substance on the outside of these cells called CD7. CD7 antibodies have been used to treat people with T-cell leukemia and lymphoma. For this study, anti-CD7 has been changed so that instead of floating free in the blood it is now joined to the T cells. When an antibody is joined to a T cell in this way it is called a chimeric receptor. In the laboratory, investigators have also found that T cells work better if they also add proteins that stimulate T cells, such as one called CD28. Adding the CD28 makes the cells grow better and last longer in the body, thus giving the cells a better chance of killing the leukemia or lymphoma cells. In this study, investigators attach the CD7 chimeric receptor with CD28 added to it to T cells. Investigators will then test how long the cells last. These CD7 chimeric receptor T cells with CD28 are investigational products not approved by the Food and Drug Administration.
Recruiting1 award Phase 1
More about LaQuisa HIll, MD
Clinical Trial Related1 year of experience running clinical trials · Led 5 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments LaQuisa HIll, MD has experience with
- CD7.CAR/28zeta CAR T Cells
- Cyclophosphamide
- Fludarabine
- Donor Search Prognosis Score
- MB-105
- CLL-1.CAR T Cells
Breakdown of trials LaQuisa HIll, MD has run
Acute Lymphoblastic Leukemia
Acute Myelogenous Leukemia
Acute Myeloid Leukemia
Acute T-Cell Leukemia
Non-Hodgkin's Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does LaQuisa HIll, MD specialize in?
LaQuisa HIll, MD focuses on Acute Lymphoblastic Leukemia and Acute Myelogenous Leukemia. In particular, much of their work with Acute Lymphoblastic Leukemia has involved CD7 positive patients, or patients who are undergoing treatment.
Is LaQuisa HIll, MD currently recruiting for clinical trials?
Yes, LaQuisa HIll, MD is currently recruiting for 2 clinical trials in Houston Texas. If you're interested in participating, you should apply.
Are there any treatments that LaQuisa HIll, MD has studied deeply?
Yes, LaQuisa HIll, MD has studied treatments such as CD7.CAR/28zeta CAR T cells, Cyclophosphamide, Fludarabine.
What is the best way to schedule an appointment with LaQuisa HIll, MD?
Apply for one of the trials that LaQuisa HIll, MD is conducting.
What is the office address of LaQuisa HIll, MD?
The office of LaQuisa HIll, MD is located at: Baylor College of Medicine, Houston, Texas 77030 United States. This is the address for their practice at the Baylor College of Medicine.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.